75425-27-3

Usage

Uses

Used in Pharmaceutical Industry:
8,8-dimethyl-3-(2,4,5-trimethoxyphenyl)-4H,8H-pyrano[2,3-f]chromen-4-one is used as a pharmaceutical candidate for its potential bioactivity and pharmacological properties. Its unique chemical structure allows it to be studied for various therapeutic applications, including the development of new drugs and treatments.
Used in Drug Development:
8,8-dimethyl-3-(2,4,5-trimethoxyphenyl)-4H,8H-pyrano[2,3-f]chromen-4-one is used in drug development for its potential to exhibit various pharmacological properties. Researchers are interested in exploring its bioactivity and evaluating its efficacy in treating different medical conditions, making it a valuable compound for the development of novel therapeutic agents.
Used in Medicinal Chemistry Research:
8,8-dimethyl-3-(2,4,5-trimethoxyphenyl)-4H,8H-pyrano[2,3-f]chromen-4-one is used as a subject of study in medicinal chemistry research. Its unique chemical structure and potential bioactivity make it an interesting compound for understanding the relationship between chemical structure and biological activity, which is crucial for the design and development of new drugs.

Upstream product

• 24672-84-2 6-acetyl-5-hydroxy-2,2-dimethylchromene 
• 91735-53-4 2',4'-Dibenzyloxy-2,4,5-trimethoxychalcone epoxide 
• 91735-52-3 2',4'-Dibenzyloxy-2,4,5-trimethoxychalcone 
• 91735-51-2 4'-Benzyloxy-2'-hydroxy-2,4,5-trimethoxychalcone 
• 4460-86-0 asaraldehyde 
• 1111-97-3 3-chloro-3-methylbut-1-yne 
• 29096-94-4 7-hydroxy-3-(2,4,5-trimethoxyphenyl)-4H-chromen-4-one 

Relevant academic research and scientific papers

Synthesis and biological evaluation of pyranoisoflavone derivatives as anti-inflammatory agents

In this paper, barbigerone (1a) and its twenty-seven related structural analogues were synthesized via complementary synthetic routes and their anti-inflammatory effects on the expression of TNF-α in LPS-stimulated splenocytes were evaluated. Among these compounds, 1a, 1d, 1f and 1g were found to remarkably inhibit TNF-α production. Furthermore, 1g showed the most potent and dose-dependent manner inhibitory effect on TNF-α release, with better IC50 value (3.58 μM) than barbigerone (8.46 μM). Oral administration of 1g at 20 mg/kg/day for two weeks obviously demonstrated protective effect in adjuvant-induced arthritis models as evaluated by clinical score of paws, and histological examination of joint tissues from rats. Mechanism studies on mRNA and protein level suggested that 1g inhibited the TNF-α production via depressing TNF-α converting enzyme (TACE) mRNA expression. In conclusion, these data show 1g with potential therapeutic effects as an anti-inflammatory agent.

Synthesis of Barbigerone, a Naturally Occurring Pyranoisoflavone

4'-Benzyloxy-2'-hydroxy-2,4,5-trimethoxychalcone (III) on benzylation gives 2',4'-dibenzyloxy-2,4,5-trimethoxychalcone (IV), which on epoxidation furnishes the corresponding epoxide (V).The latter on rearrangement with BF3-etherate gives 7-hydroxy-2',4',5'-trimethoxyisoflavone (II), via α-formyldesoxybenzoin (VI).II on reaction with 2-methyl-2-chlorobut-3-yne furnishes barbigerone (I), identical with a natural sample.